PMID- 24764706
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140425
LR  - 20211021
IS  - 1198-0052 (Print)
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Linking)
VI  - 21
IP  - 2
DP  - 2014 Apr
TI  - Potential drug interactions in patients with a history of cancer.
PG  - e212-20
LID - 10.3747/co.21.1657 [doi]
AB  - BACKGROUND: Cancer survivors (css) are frequently exposed to polypharmacy, which 
      might increase their risk of drug interactions. Our study aimed to determine the 
      relative prevalence of potential drug interactions (pdis) among css compared with 
      non-cancer respondents (ncrs). METHODS: Self-reported prescription data from 4975 
      patients were extracted from the U.S. National Health and Nutrition Examination 
      Survey and screened for pdis using iFacts: Drug Interaction Facts (Facts and 
      Comparisons, St. Louis, MO, U.S.A.). The clinical significance of each pdi was 
      graded on a 5-point scale based on the severity of the interaction and the level 
      of evidence documenting the interaction. Summary statistics and logistic 
      regression models were used to assess the impact of cancer history on the risk of 
      pdis. RESULTS: Of patients eligible for the analyses, the css (n = 302) indicated 
      using 4.4 +/- 0.22 prescriptions on average, and the ncrs (n = 908), 3.8 +/- 0.09. 
      Nearly half of both cohorts (40% of css, 43% of ncrs) had at least 1 pdi. In both 
      cohorts, 12% were at risk for fatal or permanently debilitating effects. In 
      multivariate analyses, css were significantly less likely than ncrs to be at risk 
      for any pdis (odds ratio: 0.65; 95% confidence interval: 0.46 to 0.92; p = 0.02). 
      Advanced age and low household income were associated with pdis among css. 
      Medications most commonly prescribed to css with a pdi included metoprolol 
      (15.6%), levothyroxine (13.6%), and furosemide (11.9%). CONCLUSIONS: Although css 
      appear to be less susceptible than ncrs to pdis, the prevalence of pdis among css 
      remains suboptimal. Specific subgroups of css may be particularly prone to pdis, 
      underscoring the importance of increased vigilance.
FAU - Chen, L
AU  - Chen L
AD  - University of British Columbia, Vancouver, BC.
FAU - Cheung, W Y
AU  - Cheung WY
AD  - University of British Columbia, Vancouver, BC. ; Division of Medical Oncology, BC 
      Cancer Agency, Vancouver, BC.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
PMC - PMC3997454
OTO - NOTNLM
OT  - Polypharmacy
OT  - potential drug interactions
OT  - prescription
OT  - survivors
EDAT- 2014/04/26 06:00
MHDA- 2014/04/26 06:01
PMCR- 2014/04/01
CRDT- 2014/04/26 06:00
PHST- 2014/04/26 06:00 [entrez]
PHST- 2014/04/26 06:00 [pubmed]
PHST- 2014/04/26 06:01 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - conc-21-e212 [pii]
AID - 10.3747/co.21.1657 [doi]
PST - ppublish
SO  - Curr Oncol. 2014 Apr;21(2):e212-20. doi: 10.3747/co.21.1657.